{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:06:37Z","timestamp":1791547597284,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00405-022-07800-1","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:19:01Z","timestamp":1671815941000},"page":"2453-2461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients"],"prefix":"10.1007","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-000X","authenticated-orcid":false,"given":"Mathieu","family":"C\u00e9saire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rambeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisson","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Heutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"7800_CR1","unstructured":"Defossez G, Le Guyader\u2011Peyrou S, Uhry Z,, Grosclaude P, Colonna M, Dantony E, et al (2019) Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Volume 1 \u2013 Tumeurs solides. Saint\u2011Maurice (Fra)\u202f: Sant\u00e9 publique France, 2019. 372 p."},{"key":"7800_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"J-P Pignon","year":"2009","unstructured":"Pignon J-P, le Ma\u00eetre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol J Eur Soc Ther Radiol Oncol 92:4\u201314. https:\/\/doi.org\/10.1016\/j.radonc.2009.04.014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"7800_CR3","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/hed.24687","volume":"39","author":"F Duprez","year":"2017","unstructured":"Duprez F, Berwouts D, De Neve W et al (2017) Distant metastases in head and neck cancer. Head Neck 39:1733\u20131743. https:\/\/doi.org\/10.1002\/hed.24687","journal-title":"Head Neck"},{"key":"7800_CR4","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"7800_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"7800_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet Lond Engl 394:1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet Lond Engl"},{"key":"7800_CR7","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1200\/JCO.2019.37.15_suppl.6060","volume":"37","author":"A Psyrri","year":"2019","unstructured":"Psyrri A, Gavrielatou N, Spathis A et al (2019) Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142). J Clin Oncol 37:6060\u20136060. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.6060","journal-title":"J Clin Oncol"},{"key":"7800_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40425-018-0395-x","volume":"6","author":"WJ Ho","year":"2018","unstructured":"Ho WJ, Yarchoan M, Hopkins A et al (2018) Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer 6:84. https:\/\/doi.org\/10.1186\/s40425-018-0395-x","journal-title":"J Immunother Cancer"},{"key":"7800_CR9","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598\u20132608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol Cancer Ther"},{"key":"7800_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Sa\u00e2da-Bouzid","year":"2017","unstructured":"Sa\u00e2da-Bouzid E, Defaucheux C, Karabajakian A et al (2017) Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol 28:1605\u20131611. https:\/\/doi.org\/10.1093\/annonc\/mdx178","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7800_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01669-y","author":"C Suzuki","year":"2020","unstructured":"Suzuki C, Kiyota N, Imamura Y et al (2020) Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-020-01669-y","journal-title":"Int J Clin Oncol"},{"key":"7800_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/hed.23535","volume":"36","author":"JL Campian","year":"2014","unstructured":"Campian JL, Sarai G, Ye X et al (2014) Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 36:1747\u20131753. https:\/\/doi.org\/10.1002\/hed.23535","journal-title":"Head Neck"},{"key":"7800_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2018.08.008","volume":"86","author":"AJ Lin","year":"2018","unstructured":"Lin AJ, Rao YJ, Chin R-I et al (2018) Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. Oral Oncol 86:1\u20137. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.08.008","journal-title":"Oral Oncol"},{"key":"7800_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.radonc.2022.01.003","volume":"168","author":"D Dai","year":"2022","unstructured":"Dai D, Tian Q, Shui Y et al (2022) The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: a systematic review and meta-analysis. Radiother Oncol J Eur Soc Ther Radiol Oncol 168:28\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.003","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"7800_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1567-5769(03)00013-4","volume":"3","author":"EL Verastegui","year":"2003","unstructured":"Verastegui EL, Morales RB, Barrera-Franco JL et al (2003) Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol 3:1093\u20131104. https:\/\/doi.org\/10.1016\/S1567-5769(03)00013-4","journal-title":"Int Immunopharmacol"},{"key":"7800_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejca.2017.07.033","volume":"84","author":"R Sun","year":"1990","unstructured":"Sun R, Champiat S, Dercle L et al (1990) 2017) Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1\/PD-L1 inhibitors. Eur J Cancer Oxf Engl 84:202\u2013211. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.033","journal-title":"Eur J Cancer Oxf Engl"},{"key":"7800_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D et al (2018) Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 6:74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1","journal-title":"J Immunother Cancer"},{"key":"7800_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/mco.2020.2157","volume":"13","author":"JC Park","year":"2020","unstructured":"Park JC, Durbeck J, Clark JR (2020) Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. Mol Clin Oncol 13:87. https:\/\/doi.org\/10.3892\/mco.2020.2157","journal-title":"Mol Clin Oncol"},{"key":"7800_CR19","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","volume":"8","author":"A Diehl","year":"2017","unstructured":"Diehl A, Yarchoan M, Hopkins A et al (2017) Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8:114268\u2013114280. https:\/\/doi.org\/10.18632\/oncotarget.23217","journal-title":"Oncotarget"},{"key":"7800_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/07357907.2013.767342","volume":"31","author":"JL Campian","year":"2013","unstructured":"Campian JL, Ye X, Brock M, Grossman SA (2013) Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 31:183\u2013188. https:\/\/doi.org\/10.3109\/07357907.2013.767342","journal-title":"Cancer Invest"},{"key":"7800_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2362.2005.01499.x","volume":"35","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Gourgoulis GM, Moulopoulos LA et al (2005) Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest 35:380\u2013387. https:\/\/doi.org\/10.1111\/j.1365-2362.2005.01499.x","journal-title":"Eur J Clin Invest"},{"key":"7800_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors T, Farber DL (2018) Human T cell development, localization, and function throughout life. Immunity 48:202\u2013213. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.007","journal-title":"Immunity"},{"key":"7800_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120512","author":"Y Cho","year":"2018","unstructured":"Cho Y, Kim JW, Yoon HI et al (2018) The prognostic significance of neutrophil-to-lymphocyte ratio in head and neck cancer patients treated with radiotherapy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm7120512","journal-title":"J Clin Med"},{"key":"7800_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ejca.2012.11.003","volume":"49","author":"J P\u00e9ron","year":"1990","unstructured":"P\u00e9ron J, Cropet C, Tredan O et al (1990) (2013) CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer Oxf Engl 49:1080\u20131089. https:\/\/doi.org\/10.1016\/j.ejca.2012.11.003","journal-title":"Eur J Cancer Oxf Engl"},{"key":"7800_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12885-022-09628-8","volume":"22","author":"G Eberst","year":"2022","unstructured":"Eberst G, Vernerey D, Laheurte C et al (2022) Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. BMC Cancer 22:529. https:\/\/doi.org\/10.1186\/s12885-022-09628-8","journal-title":"BMC Cancer"},{"key":"7800_CR26","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383\u20135391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3845","journal-title":"Cancer Res"},{"key":"7800_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/hed.26997","volume":"44","author":"Y Takenaka","year":"2022","unstructured":"Takenaka Y, Oya R, Takemoto N, Inohara H (2022) Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Head Neck 44:1237\u20131245. https:\/\/doi.org\/10.1002\/hed.26997","journal-title":"Head Neck"},{"key":"7800_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091324","author":"K Bal\u00e1zs","year":"2019","unstructured":"Bal\u00e1zs K, Kis E, Badie C et al (2019) Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients. Cancers. https:\/\/doi.org\/10.3390\/cancers11091324","journal-title":"Cancers"},{"key":"7800_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/annonc\/mdy507","volume":"30","author":"M Oliva","year":"2019","unstructured":"Oliva M, Spreafico A, Taberna M et al (2019) Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol 30:57\u201367. https:\/\/doi.org\/10.1093\/annonc\/mdy507","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7800_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98811","author":"GJ Hanna","year":"2018","unstructured":"Hanna GJ, Lizotte P, Cavanaugh M et al (2018) Frameshift events predict anti-PD-1\/L1 response in head and neck cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.98811","journal-title":"JCI Insight"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07800-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:17:21Z","timestamp":1680283041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7800"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07800-1","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study has received the approval of the CNIL and the Ethics Committee of the Fran\u00e7ois Baclesse Center. A non-opposition briefing note for patients living at the time of inclusion was issued to the various participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}